Clear Street Lifts Price Target on Editas (EDIT) Medicine Amid Pipeline Progress
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds.
Editas Medicine Inc. (EDIT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ADAR1 Capital Management Daniel Schneeberger | 8,889,000 | $28,800,360 | 1.32% | |
| 2. | RA Capital Management Peter Kolchinsky | 8,889,000 | $28,800,360 | 0.25% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 8,889,000 | $28,800,360 | 1.72% | |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 5,586,625 | $18,100,665 | 0.34% | |
| 5. | Opaleye Management James A. Silverman | 3,861,930 | $12,512,653 | +101% | 1.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.64 | 45,000 | $253,867.50 | 67,700 | 2024-05-13 | Filing | |
| $45.51 | 5,800 | $263,969.60 | 22,700 | 2021-03-03 | Filing | |
| $46.27 | 25,000 | $1,156,800.00 | 35,000 | 2021-03-02 | Filing | |
| $23.94 | 10,200 | $244,188.00 | 16,900 | 2019-03-05 | Filing | |
| $38.03 | 10,000 | $380,252.00 | 10,000 | 2018-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.58 | 678 | $1,749.24 | 14,292 | 2026-08-03 | Filing | |
| $2.67 | 4,928 | $13,157.76 | 62,369 | 2026-07-28 | Filing | |
| $2.70 | 464 | $1,253.26 | 14,970 | 2026-06-03 | Filing | |
| $2.70 | 15,380 | $41,542.92 | 248,313 | 2026-06-03 | Filing | |
| $2.70 | 731 | $1,974.50 | 67,297 | 2026-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,589,990 | $34,311,568 | 0% | |
| 2. | 6,141,336 | $19,897,929 | 0% | |
| 3. | 3,598,339 | $11,658,618 | 0% | |
| 4. | 2,569,072 | $8,325,643 | 0% | |
| 5. | 2,191,803 | $7,101,442 | 0% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program
Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target.
10 Best Performing Penny Stocks to Buy Now
Long-lagging small-cap and penny stocks are increasingly capturing the attention of value investors.
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Editas Medicine’s Second Quarter 2024 Conference Call. All participants are now in a listen-only mode.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.